Between 2018 and 2021, several targeted drug therapies achieved FDA approval for use in cholangiocarcinoma based on specific gene alterations identifiable by next-generation sequencing. Comprehensive genetic profiling is now widely supported by US and international guidelines to support therapeutic decision-making in this disease.
Notably, ASCO selected the role of molecular profiling in driving progress in GI cancers as the 2021 Advance of the Year in oncology, including biliary tract and gall bladder cancers. As these cancers are represented by biologically different tumor subtypes, next-generation sequencing through both tumor-tissue panels and blood-based "liquid biopsy" tests for circulating tumor DNA critically inform oncologists on which genetic alterations may be targetable drivers of individual patients' tumors. This knowledge facilitates the selection of optimal therapies and/or enrollments into specific clinical trials, leading to better outcomes for patients.
In this presentation, Calvin Chao, MD, Sr Vice President of Medical Affairs at Tempus will review a current update of diagnostic and therapeutic advances in cholangiocarcinoma, with a focus on the central role of molecular testing platforms.
Precision Medicine in Cholangiocarcinoma: How Comprehensive Molecular Profiling Identifies Personalized Treatment Options for Patients
Thurs., Oct. 28, 2021
Calvin Chao, MD is Sr Vice President of Medical Affairs at Tempus Labs, Inc. He manages a team of medical and scientific professionals responsible for medical oncology research collaborations, education, and physician support services. Dr. Chao has over 20 years' experience in oncology precision diagnostics and pharmaceutical medical affairs experience, and 10 years' experience as a clinician and healthcare system leader in internal medicine.